Generic Drugs Market in India 2017
The report is sent in 0-2 business days after order is placed.
Netscribes’ latest market research report titled Generic Drugs Market in India 2017 covers the current and future state of the generics market in the country. Demand for generics is expected to increase as patients shift from the more expensive branded drugs to the lower priced generics. Various initiatives from the government to increase the usage of generics instead of branded drugs, wherever possible, are also helping in the growth of the market. Setting up of a large number of Jan Aushadhi stores is making generics more accessible. Moreover, government’s proposal in Jul 2016 whereby physicians would have to mention generic names of drugs instead of names of branded drugs is expected to further boost the market.
Generic drug manufacturers operating in India have a distinct cost advantage when it comes to manufacturing. The low manufacturing costs in the country enable Indian companies to manufacture generic drugs at costs lower than the cost at which companies operating in regulated markets manufacture. Consequently, this has created a huge export opportunity for Indian companies. The US is one of the largest importers of generic drugs from India. Recently, regulatory warnings from foreign regulatory bodies such as the USFDA regarding lapses in product quality and for not adhering to stipulated manufacturing standards have led to a negative perception of generics manufactured in India. The industry, however, realizes the importance of these export markets and is taking remedial steps to ensure that such negative perceptions are removed.
COVERAGE:
Netscribes’ latest market research report titled Generic Drugs Market in India 2017 covers the current and future state of the generics market in the country. Demand for generics is expected to increase as patients shift from the more expensive branded drugs to the lower priced generics. Various initiatives from the government to increase the usage of generics instead of branded drugs, wherever possible, are also helping in the growth of the market. Setting up of a large number of Jan Aushadhi stores is making generics more accessible. Moreover, government’s proposal in Jul 2016 whereby physicians would have to mention generic names of drugs instead of names of branded drugs is expected to further boost the market.
Generic drug manufacturers operating in India have a distinct cost advantage when it comes to manufacturing. The low manufacturing costs in the country enable Indian companies to manufacture generic drugs at costs lower than the cost at which companies operating in regulated markets manufacture. Consequently, this has created a huge export opportunity for Indian companies. The US is one of the largest importers of generic drugs from India. Recently, regulatory warnings from foreign regulatory bodies such as the USFDA regarding lapses in product quality and for not adhering to stipulated manufacturing standards have led to a negative perception of generics manufactured in India. The industry, however, realizes the importance of these export markets and is taking remedial steps to ensure that such negative perceptions are removed.
COVERAGE:
- Overview of the generics drugs market in India, and historical and forecasted market size data over 2012 to 2020
- Trade analysis of pharmaceutical products in India
- Qualitative analysis of the major factors driving growth in the market, and the key challenges affecting the market
- Analysis of the competitive landscape and profiles of major public and private players operating in the market
- Key recent developments in the Indian generic drugs market
- Get a broad understanding of the food processing industry in India, the dynamics of the market and the current state of the industry
- Gain knowledge to devise suitable marketing, market-entry, and other business strategies
- Identify key growth drivers in the market and make informed decisions to benefit from them and increase profitability
- Understand the business operations and strategies of key competitors’, and respond accordingly
Slide 1: Executive Summary
SOCIOECONOMIC INDICATORS
Slide 2: Total Population (2010-2011 – 2019-2020), Population Density (2010-2011 – 2019-2020)
Slide 3: Sex Ratio (2005, 2010, 2015, 2020), Population by Age Group (2005, 2010, 2015, 2020), Urbanization Trend (2010-2011 – 2019-2020)
Slide 4: Total Fertility Rate (2005-2010, 2010-2015, 2015-2020), Infant Mortality Rate (2005-2010, 2010-2015, 2015-2020), Total Number of Births (2005-2010, 2010-2015, 2015-2020), Total Number of Death (2005-2010, 2010-2015, 2015-2020)
Slide 5: Total Literacy Rate (2001, 2011), Rural Literacy (2001, 2011), Urban Literacy (2001, 2011)
Slide 6: GDP at Market Prices (2010-2014), FDI (2010-2014), Inflation Rate (2010-2014), Unemployment Rate (2010-2014)
Slide 7: Access to Safe Drinking Water (2001, 2011), Exchange Rate (2010-2015)
MARKET OVERVIEW
Slide 8: Market Definition & Structure
Slide 9: Generic Drugs Market in India – Market Overview, Size and Growth (2012 – 2020e)
Slide 10: Porter’s Five Forces Analysis
TRADE ANALYSIS
Slide 11: Export of Medicaments Consisting of Two or More Constituents Mixed Together for Human Medicine Not for Retail Sale – Size (Value-Wise; FY 2013 – FY 2017(Apr-Dec)) and Country-Wise Segmentation (Value-Wise; FY 2015 and FY 2016)
Slide 12: Import of Medicaments Consisting of Two or More Constituents Mixed Together for Human Medicine Not for Retail Sale – Size (Value-Wise; FY 2013 – FY 2017(Apr-Dec)) and Country-Wise Segmentation (Value-Wise; FY 2015 and FY 2016)
Slide 13: Export of Medicaments Consisting of Medicaments for Therapeutic or Prophylactic Uses in Measured Doses or in Packing for Retail Sale – Size (Value-Wise; FY 2013 – FY 2017(Apr-Dec)) and Country-Wise Segmentation (Value-Wise; FY 2015 and FY 2016)
Slide 14: Import of Medicaments Consisting of Medicaments for Therapeutic or Prophylactic Uses in Measured Doses or in Packing for Retail Sale – Size (Value-Wise; FY 2013 – FY 2017(Apr-Dec)) and Country-Wise Segmentation (Value-Wise; FY 2015 and FY 2016)
Slide 15: Export of Drugs and Medicines – Size (Value-Wise; FY 2013 – FY 2017(Apr-Dec)) and Country-Wise Segmentation (Value-Wise; FY 2015 and FY 2016)
Slide 16: Import of Drugs and Medicines – Size (Value-Wise; FY 2013 – FY 2017(Apr-Dec)) and Country-Wise Segmentation (Value-Wise; FY 2015 and FY 2016)
MARKET INFLUENCERS
Slide 17-18: Market Drivers
Slide 19: Market Challenges
COMPETITIVE LANDSCAPE
Slide 20: List of Major Players
Slide 21-60: Profiles of Major Players
RECENT DEVELOPMENTS
Slide 61-63: Key Strategic Recommendations
APPENDIX
Slide 64: Research Methodology
SOCIOECONOMIC INDICATORS
Slide 2: Total Population (2010-2011 – 2019-2020), Population Density (2010-2011 – 2019-2020)
Slide 3: Sex Ratio (2005, 2010, 2015, 2020), Population by Age Group (2005, 2010, 2015, 2020), Urbanization Trend (2010-2011 – 2019-2020)
Slide 4: Total Fertility Rate (2005-2010, 2010-2015, 2015-2020), Infant Mortality Rate (2005-2010, 2010-2015, 2015-2020), Total Number of Births (2005-2010, 2010-2015, 2015-2020), Total Number of Death (2005-2010, 2010-2015, 2015-2020)
Slide 5: Total Literacy Rate (2001, 2011), Rural Literacy (2001, 2011), Urban Literacy (2001, 2011)
Slide 6: GDP at Market Prices (2010-2014), FDI (2010-2014), Inflation Rate (2010-2014), Unemployment Rate (2010-2014)
Slide 7: Access to Safe Drinking Water (2001, 2011), Exchange Rate (2010-2015)
MARKET OVERVIEW
Slide 8: Market Definition & Structure
Slide 9: Generic Drugs Market in India – Market Overview, Size and Growth (2012 – 2020e)
Slide 10: Porter’s Five Forces Analysis
TRADE ANALYSIS
Slide 11: Export of Medicaments Consisting of Two or More Constituents Mixed Together for Human Medicine Not for Retail Sale – Size (Value-Wise; FY 2013 – FY 2017(Apr-Dec)) and Country-Wise Segmentation (Value-Wise; FY 2015 and FY 2016)
Slide 12: Import of Medicaments Consisting of Two or More Constituents Mixed Together for Human Medicine Not for Retail Sale – Size (Value-Wise; FY 2013 – FY 2017(Apr-Dec)) and Country-Wise Segmentation (Value-Wise; FY 2015 and FY 2016)
Slide 13: Export of Medicaments Consisting of Medicaments for Therapeutic or Prophylactic Uses in Measured Doses or in Packing for Retail Sale – Size (Value-Wise; FY 2013 – FY 2017(Apr-Dec)) and Country-Wise Segmentation (Value-Wise; FY 2015 and FY 2016)
Slide 14: Import of Medicaments Consisting of Medicaments for Therapeutic or Prophylactic Uses in Measured Doses or in Packing for Retail Sale – Size (Value-Wise; FY 2013 – FY 2017(Apr-Dec)) and Country-Wise Segmentation (Value-Wise; FY 2015 and FY 2016)
Slide 15: Export of Drugs and Medicines – Size (Value-Wise; FY 2013 – FY 2017(Apr-Dec)) and Country-Wise Segmentation (Value-Wise; FY 2015 and FY 2016)
Slide 16: Import of Drugs and Medicines – Size (Value-Wise; FY 2013 – FY 2017(Apr-Dec)) and Country-Wise Segmentation (Value-Wise; FY 2015 and FY 2016)
MARKET INFLUENCERS
Slide 17-18: Market Drivers
Slide 19: Market Challenges
COMPETITIVE LANDSCAPE
Slide 20: List of Major Players
Slide 21-60: Profiles of Major Players
RECENT DEVELOPMENTS
Slide 61-63: Key Strategic Recommendations
APPENDIX
Slide 64: Research Methodology
